ACIU Current Deferred Revenue vs Net Receivables Analysis
ACIU Stock | USD 2.48 0.08 3.33% |
AC Immune financial indicator trend analysis is way more than just evaluating AC Immune prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AC Immune is a good investment. Please check the relationship between AC Immune Current Deferred Revenue and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.
Current Deferred Revenue vs Net Receivables
Current Deferred Revenue vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AC Immune Current Deferred Revenue account and Net Receivables. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between AC Immune's Current Deferred Revenue and Net Receivables is -0.17. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Receivables in the same time period over historical financial statements of AC Immune, assuming nothing else is changed. The correlation between historical values of AC Immune's Current Deferred Revenue and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of AC Immune are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Current Deferred Revenue i.e., AC Immune's Current Deferred Revenue and Net Receivables go up and down completely randomly.
Correlation Coefficient | -0.17 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Net Receivables
Most indicators from AC Immune's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AC Immune current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.At this time, AC Immune's Tax Provision is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 486.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 8.3 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 79.0M | 74.8M | 68.4M | 55.9M | Cost Of Revenue | 62.3M | 60.3M | 54.6M | 45.8M |
AC Immune fundamental ratios Correlations
Click cells to compare fundamentals
AC Immune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AC Immune fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 299.3M | 238.7M | 261.4M | 185.9M | 182.8M | 177.6M | |
Other Current Liab | 11.8M | 11.1M | 16.7M | 9.4M | 11.1M | 9.5M | |
Total Current Liabilities | 17.5M | 14.0M | 20.0M | 11.5M | 13.6M | 12.8M | |
Total Stockholder Equity | 272.4M | 215.5M | 232.0M | 169.0M | 160.6M | 158.5M | |
Other Liab | 7.5M | 7.5M | 7.1M | 3.2M | 3.7M | 5.0M | |
Net Tangible Assets | 272.4M | 215.5M | 181.6M | 118.6M | 136.4M | 145.5M | |
Retained Earnings | (75.5M) | (132.9M) | (200.9M) | (264.0M) | (316.2M) | (300.4M) | |
Accounts Payable | 142K | 2.2M | 2.0M | 929K | 1.7M | 1.4M | |
Cash | 193.6M | 160.9M | 82.2M | 31.6M | 78.5M | 107.1M | |
Net Receivables | 1.4M | 1.9M | 1.4M | 800K | 15.7M | 16.5M | |
Other Current Assets | 4.2M | 5.9M | 4.4M | 4.7M | 7.1M | 7.4M | |
Total Liab | 26.8M | 23.3M | 29.5M | 16.9M | 22.2M | 19.1M | |
Total Current Assets | 292.8M | 231.8M | 202.6M | 128.1M | 125.2M | 157.9M | |
Common Stock | 1.4M | 1.5M | 1.8M | 1.8M | 2.1M | 1.5M | |
Property Plant Equipment | 6.2M | 6.6M | 8.0M | 7.1M | 8.1M | 8.5M | |
Property Plant And Equipment Net | 6.2M | 6.6M | 8.0M | 7.1M | 6.9M | 4.7M | |
Current Deferred Revenue | 4.5M | 306K | 717K | 587K | 138K | 131.1K | |
Net Debt | (190.7M) | (158.7M) | (79.3M) | (28.8M) | (75.0M) | (78.7M) | |
Non Current Assets Total | 6.5M | 7.0M | 58.8M | 57.8M | 57.7M | 60.5M | |
Non Currrent Assets Other | 6.5M | 334K | 363K | 361K | 415.2K | 394.4K | |
Cash And Short Term Investments | 288.6M | 225.9M | 198.2M | 122.6M | 103.0M | 162.9M | |
Common Stock Total Equity | 1.1M | 1.4M | 1.4M | 1.5M | 1.8M | 1.3M | |
Common Stock Shares Outstanding | 71.1M | 71.9M | 75.0M | 83.6M | 84.7M | 73.3M | |
Short Term Investments | 95M | 65M | 116M | 91M | 24.6M | 46.4M | |
Liabilities And Stockholders Equity | 299.3M | 238.7M | 261.4M | 185.9M | 182.8M | 193.9M | |
Non Current Liabilities Total | 9.3M | 9.2M | 9.4M | 5.5M | 8.6M | 6.9M | |
Capital Lease Obligations | 2.3M | 2.2M | 2.9M | 2.8M | 3.5M | 3.7M | |
Inventory | (1.4M) | (1.9M) | (1.4M) | 1.0 | (622K) | (590.9K) | |
Other Stockholder Equity | 346.5M | 346.8M | 431.1M | 431.2M | 474.8M | 300.1M | |
Property Plant And Equipment Gross | 6.2M | 6.6M | 15.6M | 7.1M | 17.9M | 18.8M | |
Accumulated Other Comprehensive Income | 179.4M | (3.5M) | 0.0 | 10K | (51K) | (48.5K) | |
Short Term Debt | 1.1M | 443K | 570K | 548K | 672K | 402.5K | |
Short Long Term Debt Total | 2.9M | 2.2M | 2.9M | 2.8M | 3.5M | 2.1M | |
Net Invested Capital | 273.1M | 215.5M | 232.0M | 169.0M | 160.6M | 211.4M | |
Net Working Capital | 275.3M | 217.7M | 182.6M | 116.6M | 111.6M | 137.5M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AC Immune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AC Immune's short interest history, or implied volatility extrapolated from AC Immune options trading.
Pair Trading with AC Immune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AC Immune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AC Immune will appreciate offsetting losses from the drop in the long position's value.Moving together with ACIU Stock
0.65 | EVOK | Evoke Pharma | PairCorr |
Moving against ACIU Stock
0.61 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
0.53 | ELYM | Eliem Therapeutics Trending | PairCorr |
0.46 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
0.44 | IBIO | Ibio Inc | PairCorr |
The ability to find closely correlated positions to AC Immune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AC Immune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AC Immune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AC Immune to buy it.
The correlation of AC Immune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AC Immune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AC Immune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AC Immune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for ACIU Stock analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements |
Is AC Immune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AC Immune. If investors know ACIU will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AC Immune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Revenue Per Share 0.175 | Quarterly Revenue Growth 14.8 K | Return On Assets (0.18) | Return On Equity (0.33) |
The market value of AC Immune is measured differently than its book value, which is the value of ACIU that is recorded on the company's balance sheet. Investors also form their own opinion of AC Immune's value that differs from its market value or its book value, called intrinsic value, which is AC Immune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AC Immune's market value can be influenced by many factors that don't directly affect AC Immune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AC Immune's value and its price as these two are different measures arrived at by different means. Investors typically determine if AC Immune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AC Immune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.